hla dr pe  (Immunostep)

Journal: Cell Reports Medicine

Article Title: Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS

doi: 10.1016/j.xcrm.2026.102749

Figure Lengend Snippet: Primary AML and MDS blasts show high sensitivity to Debio 1562M in vitro , as well as AML LSCs (A–E) Unsorted blood cells from patients with AML ( n = 31) were assessed for (A) levels of CD37 expression and (B) levels of internalization of labeled Debio 1562M (Debio 1562M-pHRodo MFI). AML blasts were identified using CD45 and CD34 markers, B cells using CD19, and T cells using CD3. (C) The same AML samples were cultured in the presence of increasing doses of Debio 1562M and the viability of the malignant blasts assessed. (D) AML patient samples classified by mutational or pre-treatment status versus sensitivity to Debio 1562M (IC50). (E) Viability of AML blasts and normal B and T cells at 100 nM dose of Debio 1562M are shown. (F) Relative colony-forming units of primary AML samples ( n = 13) following incubation with vehicle, an isotype antibody ADC, or Debio 1562M (1 or 10 nM) for 48 h. (G–J) Unsorted blood cells from patients with MDS ( n = 15) were assessed for (G) levels of CD37 expression and (H) levels of internalization of labeled Debio 1562M (Debio 1562M-pHRodo MFI). MDS blasts were identified using CD34, CD33, and HLA-DR markers; B cells using CD19; and T cells using CD3. (I) The MDS samples analyzed above were cultured in the presence of increasing doses of Debio 1562M and the viability of the malignant blasts assessed. (J) Viability of MDS blasts and normal B and T cells at 100 nM dose of Debio 1562M are shown. Shown are mean ± SEM. One-way ANOVA multiple comparison was used for statistical analysis ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. See also and and and .

Article Snippet: Combinations of the following antibodies were used for flow cytometry: naratuximab [20nM; Debiopharm], CD19-PE-Cy7 [0.5μg/ml; Beckman Coulter], CD33-APC [0.9 μg/mL Biolegend], CD3-APC-H7 [1.5 μg/mL; BD Biosciences], CD19-APC-Cy7 [1.255 μg/mL; Biolegend], CD33-BV450 [1 μg/mL; BD Biosciences], HLA-DR-PE [25 μg/mL Immunostep], CD45-BV510 [2.5 μg/mL; Fisher Scientific], CD64-BV605 [3.5 μg/mL; Biolegend], CD34-PE-Cy7 [1.5 μg/mL; Biolegend], CD123-APC [1.5 μg/mL; Biolegend], CD3-AF700 [3.5 μg/mL; Biolegend].

Techniques: In Vitro, Expressing, Labeling, Cell Culture, Incubation, Comparison

Journal: iScience

Article Title: Hypoxic-immune axis orchestrates metastatic dissemination via HIF isoform imbalance in pancreatic neuroendocrine tumors

doi: 10.1016/j.isci.2025.114340

Figure Lengend Snippet: Immune cell infiltration in KRAS G12C mutant PNETs (A) Quantitative analysis using Image Plus 6.0 software reveals a significant increase in Tregs (CD4 + , CD25 + , and FoxP3 + ) within KRAS- G12C mutant PNETs compared to wild-type KRAS PNET tissues, suggesting KRAS G12C -driven immunosuppressive cell recruitment. (B) Fluorescence intensity analysis demonstrates reduced infiltration of CD8 + cytotoxic T cells and HLA-DR + activated cells in KRAS G12C mutant tumors, indicative of impaired antitumor immunity. (C) Elevated MDSCs counts in KRAS G12C mutant PNETs correlate with enhanced immune evasion.

Article Snippet: PE Anti-Human HLA-DR Antibody [L243] , Elabscience , E-AB-F1111D.

Techniques: Mutagenesis, Software, Fluorescence

Journal: iScience

Article Title: Hypoxic-immune axis orchestrates metastatic dissemination via HIF isoform imbalance in pancreatic neuroendocrine tumors

doi: 10.1016/j.isci.2025.114340

Figure Lengend Snippet: Tregs, CD8 + T cells, and HLA-DR + cells in KRAS G12C -mutated PNETs (A) Flow cytometry plots and fluorescence intensity histograms demonstrate elevated CD4 + T cell proportions in KRAS G12C patient blood samples compared to wild-type KRAS tumors and healthy controls. (B) Quantification shows a significant enrichment of CD25 + T cells in KRAS G12C patients, surpassing both wild-type KRAS tumors and normal controls. (C) Quantitative data and histogram overlays confirm a substantial increase in FoxP3 + T cells frequency in KRAS G12C patients, with levels moderately elevated compared to wild-type KRAS and significantly higher than healthy individuals. (D) A slight decrease in CD8 + T cell frequency in KRAS G12C samples relative to wild-type KRAS, with levels significantly lower than those in healthy individuals (E) A moderate reduction in HLA-DR + cell frequency in KRAS G12C patients compared to wild-type KRAS, alongside a marked suppression relative to healthy controls.

Article Snippet: PE Anti-Human HLA-DR Antibody [L243] , Elabscience , E-AB-F1111D.

Techniques: Flow Cytometry, Fluorescence